Clinical Trials

One Perspective on the BLU-285 Trial (avapritinib/Ayvakit)

LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.

By |2020-03-09T10:18:42-04:00February 28th, 2020|D842V, News, Newsletter|

LRG Webcast Series: Updates on the Temozolomide Trial

Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.

By |2020-07-09T17:44:13-04:00September 16th, 2019|Clinical Trials, SDH-Deficient GIST, Webcast|

Update on a New Clinical Trial Offered to Eligible GIST Patients

The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.

By |2019-08-21T11:40:48-04:00June 20th, 2019|Clinical Trials, News, Newsletter|
Go to Top